Determinants for changing the treatment of COPD: A regression analysis from a clinical audit

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1171-1178

  López Campos, Jose Luis ^a,b   Abad Arranz, María ^a   Calero Acuña, Carmen ^a,b   Romero Valero, Fernando ^c   Ayerbe García, Ruth ^d   Hidalgo Molina, Antonio ^c   Aguilar Perez Grovas, Ricardo I ^d   García Gil, Francisco ^e   Casas Maldonado, Francisco ^f   Caballero Ballesteros, Laura ^e   Sánchez Palop, María ^f   Pérez Tejero, Dolores ^g   Segado, Alejandro ^g   Calvo Bonachera, Jose ^h   Hernández Sierra, Bárbara ^h   Doménech, Adolfo ⁱ   Arroyo Varela, Macarena ⁱ   González Vargas, Francisco ^j   Cruz Rueda, Juan J ^j  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g HOSPITAL INFANTA MARGARITA   (Spain)

^h HOSPITAL TORRECÁRDENAS   (Spain)

ⁱ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

more..

Author keywords

Airway diseases; Follow up; Outpatient care; Quality of care; Respiratory diseases; Treatment strategies

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PATIENT COMPLIANCE; PILOT STUDY; PRACTICE GUIDELINE; REGRESSION ANALYSIS; SPAIN; SYMPTOM; CLINICAL AUDIT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE COURSE; DRUG EFFECTS; HEALTH CARE QUALITY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PHENOTYPE; PRESCRIPTION; PROTOCOL COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SECONDARY HEALTH CARE; STATISTICAL MODEL; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CLINICAL DECISION-MAKING; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; LUNG; MALE; MEDICAL AUDIT; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OUTPATIENT CLINICS, HOSPITAL; PHENOTYPE; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROCESS ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SECONDARY CARE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84973497204     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S103614     Document Type: Article

References (31)

1. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122.
2. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011; 37(2): 264-272.
3. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4): 347-365.
4. Miravitlles M. What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved? Arch Bronconeumol. 2016; 52(1): 1-2.
5. Lopez-Campos JL, Bustamante V, Munoz X, Barreiro E. Moving towards patient-centered medicine for COPD management: multidimensional approaches versus phenotype-based medicine-a critical view. COPD. 2014; 11(5): 591-602.
6. Soriano JB, Rodriguez-Roisin R. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc. 2011; 8(4): 363-367.
7. Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care. 2006; 51(3): 277-288.
8. Overington JD, Huang YC, Abramson MJ, et al. Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. J Thorac Dis. 2014; 6(11): 1586-1596.
9. Diette GB, Dalal AA, D'Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015; 10: 415-422.
10. Nardini S, Camiciottoli G, Locicero S, et al. COPD: maximization of bronchodilation. Multidiscip Respir Med. 2014; 9(1): 50.
11. Rodriguez Roisin R, Arismendi E. Inhaled corticosteroids withdrawal in severe patients with chronic obstructive pulmonary disease: a wisdom decision? Arch Bronconeumol. 2015; 51(2): 57-58.
12. Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013; 67(6): 497-515.
13. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015; 385(9971): 857-866.
14. Osthoff M, Jenkins C, Leuppi J. Chronic obstructive pulmonary disease-a treatable disease. Swiss Med Wkly. 2013; 143: w13777.
15. Lopez-Campos JL, Abad Arranz M, Calero Acuna C, et al. Clinical audits in outpatient clinics for chronic obstructive pulmonary disease: methodological considerations and workflow. PloS One. 2015; 10(11): e0141856.
16. Pozo-Rodriguez F, Alvarez CJ, Castro-Acosta A, et al. Auditoría clínica de los pacientes hospitalizados por exacerbación de EPOC en España (estudio AUDIPOC): método y organización del trabajo [Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): method and organisation]. Arch Bronconeumol. 2010; 46(7): 349-357. Spanish.
17. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016; 47(1): 113-121.
18. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014; 9: 889-904.
19. Ford ES, Mannino DM, Wheaton AG, et al. Trends in the use, sociodemographic correlates, and undertreatment of prescription medications for chronic obstructive pulmonary disease among adults with chronic obstructive pulmonary disease in the United States from 1999 to 2010. PloS One. 2014; 9(4): e95305.
20. Izquierdo JL, Martin A, de Lucas P, Rodriguez-Gonzalez-Moro JM, Almonacid C, Paravisini A. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis. 2010; 5: 241-249.
21. Flottorp SA, Jamtvedt G, Gibis B, McKee M. Using Audit and Feedback to Health Professionals to Improve the Quality and Safety of Health Care. Copenhagen: World Health Organization; 2010.
22. Lopez-Campos JL, Asensio-Cruz MI, Castro-Acosta A, et al. Results from an audit feedback strategy for chronic obstructive pulmonary disease in-hospital care: a joint analysis from the AUDIPOC and European COPD audit studies. PloS One. 2014; 9(10): e110394.
23. Nardini S, Cicchitto G, De Benedetto F, et al. Audit on the appropriateness of integrated COPD management: the "ALT-BPCO" project. Multidiscip Respir Med. 2014; 9(1): 40.
24. Glaser D, Hastings RH. An introduction to multilevel modeling for anesthesiologists. Anesth Analg. 2011; 113(4): 877-887.
25. Merlo J. Multilevel analytical approaches in social epidemiology: measures of health variation compared with traditional measures of association. J Epidemiol Community Health. 2003; 57(8): 550-552.
26. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015; 385(9979): 1789-1798.
27. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol. 2012; 48(7): 247-257.
28. Rossi A, Guerriero M, Corrado A, Group OAS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014; 15: 77.
29. Alcazar Navarrete B, Casanova C, Miravitlles M, et al. "Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease": a consensus document. Arch Bronconeumol. 2015; 51(4): 193-198.
30. Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013; 8: 501-508.
31. Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016; 47(2): 625-637.